Researchers at Stanford have designed, in silico, a series of new human IL-2 mutants that have biased actions on different immune cell subsets, and confer increased signaling potency compared to natural IL-2.
Researchers at Stanford have created a de novo protein design platform that designs binding proteins specifically interacting with the MHC-peptide complex.